Sunday 05 February 2012 'premium' content
Register   |   Forgot password?   |    AusPharmList   |    auspharmjobs.net.au   

Advertisers
and Sponsors
LOGIN  (email address)

PASSWORD

Remember me:
SEARCH SITE:
mail2web.com
CHECK YOUR EMAIL:


No polls are currently active, you can see the results from previous polls here.

Pharmaceutical Defence Limited

RIPAA



To generate a report of the AusPharm Continuing Education Activities you have completed for a specified time period (and, if desired, the number of times you have posted to AusPharmList over the same time period), click here. Please note, you need to be logged in to do this.

The Continuing Education activities below will remain active for 12 months from the date of publication. You will be able to do any one of them at any time. ie ALL activities remain 'active' not just the current activity.

While every effort has been made to ensure that material presented is accurate and up to date, new evidence is continually uncovered and what is accurate one week may not stay accurate for long.


AusPharm Continuing Education

RGH Pharmacy E-Bulletin CPD Digest - Issue No 43 :: Chris Alderman : 2/2/2012 : The next in our 2012 series of continuing education activities is the RGH E-Bulletin Digest No. 43.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 44-4 → 44-7 ⇔ Oct-Nov 2011).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

  • Understand general principles relating to the safety of drug treatment during pregnancy
  • Described the clinical pharmacology of zonisamide
  • Discuss the use of parenteral iron preparations for the management of iron deficiency anaemia
  • List issues that might impact of the drug interactions between antibiotic treatment and warfarin.

This activity has been accredited for 0.5 hours of Group 2 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan. Accreditation number: CX120022A.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








The Pharmacist's Role in Migraine Management :: Angus Thompson : 19/1/2012 : Learning objectives

On completion of this module, pharmacists should be able to

  • Recognise the range of opportunities that exist for pharmacists to optimise migraine management
  • Discuss the therapeutic options that exist for migraine.

The competency standards addressed by this activity include (but may not be limited to) 4.2.3., 4.3.3. , 6.1.1. , 6.1.2. , 6.1.3. , 6.2.2  , 7.1.2. , 7.1.3.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022f.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Preventing Pharmaceutical Poisonings :: Professor Nerida Smith : 5/1/2012 : This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

Learning Objectives

After completing this activity pharmacists should be able to describe:

  • demographics of poisoning in Australia
  • strategies used to prevent poisonings
  • types and testing for child resistant packaging used in Australia and NZ
  • sources of poison prevention information and resources in Australia and NZ.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Lifestyle factors and impact on medicines: You are what you eat! :: Debbie Rigby : 15/12/2011 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Provide practical evidence-based information on the impact of foods on medications and health outcomes
  • Advise patients on diets proven to reduce cardiovascular morbidity and mortality
  • Assess dietary modifications for prevention of gout
  • Counsel patients on calcium and vitamin D supplements for optimal bone mass and in conjunction with anti-osteoporotic medicines
  • Counsel patients with or without hypertension on the benefits of dietary salt reduction.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 6.1.2, 6.2.1, 6.2.2, 7.1.1, 7.1.2, 7.1.3, 7.1.4.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point:  Accreditation number: CX110022u.

PSA is authorised by the Australian Pharmacy Council to accredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 42 :: Chris Alderman : 1/12/2011 : The next in our 2011 series of continuing education activities is the RGH E-Bulletin Digest No. 42.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 43-12 → 44-3 ⇔ October 2011).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

  • Discuss drug therapy use for management of behavioural disturbance in patients with frontotemporal dementia
  • Understand the current guidelines for pharmacotherapy in heart failure
  • List drugs for which the likelihood of adverse reactions is increased by Gilbert's syndrome
  • Describe the clinical pharmacology of asenapine.

This activity has been accredited for 1 Group 2 CPD credit suitable for inclusion in an individual's pharmacist's CPD plan. Accreditation number: CX110022t.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Rheumatoid arthritis :: Jenny Gowan : 17/11/2011 : This AusPharm CE topic is Rheumatoid arthritis - it's been put together for us by Dr Jenny Gowan.

"Rheumatoid arthritis (RA) is a systemic inflammatory disease that initially focuses on synovial joints.  It is a lymphocyte-mediated autoimmune disease that can cause chronic inflammation of the joints and other areas of the body, including the heart, respiratory system, nerves and eyes. It can affect people of all ages. RA usually affects multiple joints on both sides of the body at the same time. The cytokines tumour necrosis factor (TNF) and interleukin-1 ((IL-1) appear to be key factors although other pro-inflammatory mediators are also involved.  The inflammation results in joint destruction with both bony erosions and cartilage loss."

The Learning Objectives for this activity are:

  • To be able to communicate with patients about the management of rheumatoid arthritis
  • To assist patients to achieve adherence to medication regimens to treat rheumatoid arthritis and its associated complications
  • To  identify adverse effects from medications used  to treat rheumatoid arthritis
  • To ensure that patients undergo regular monitoring to minimise adverse effects from medications used to treat arthritis.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 1.3, 4.2, 7.1, 7.2, 7.3.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points.
Accreditation number: CX110022s.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 41 :: Chris Alderman : 3/11/2011 : The next in our 2011 series of continuing education activities is the RGH E-Bulletin Digest No. 41.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 43-8 → 43-11 ⇒ September 2011).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

  • Understand the prevalence and characteristics of dermatological reactions to lamotrigine
  • Describe the approach to treatment for psoriatic arthritis
  • Identify features of neutropaenia, particularly as these relate to an adverse reaction to  mirtazapine
  • List characteristics of photosensitivity reactions to drugs.

This activity has been accredited for 1 Group 2 CPD credit suitable for inclusion in an individual's pharmacist's CPD plan.
Accreditation number: CX110022r.

PSA is authorised by the Australian Pharmacy Council to accredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Dyslipidaemia :: Angus Thompson : 19/10/2011 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss the factors that influence commencement of medication for dyslipidaemia
  • Describe the target lipid levels appropriate for different patient groups
  • Outline the role of the various drug therapy options in managing dyslipidaemia
  • Identify patients at higher risk of toxicity from dyslipidaemia therapy.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 7.1.2, 7.1.3, 7.2.2, 7.2.3.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point.
Accreditation number: CX110022q.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 40 :: Chris Alderman : 6/10/2011 : The next in our 2011 series of continuing education activities is the RGH E-Bulletin Digest No. 40.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 43-4 → 43-7 ⇒ August 2011).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

  • List strategies that can be used for antidepressant augmentation
  • Understand the risk factors for hyperammonaemia secondary to valproate
  • Describe the relationship between atrial fibrillation and NSAID use
  • Discuss the clinical features of hyperparathyroidism.

This activity has been accredited for 1 Group 2 CPD credit suitable for inclusion in an individual's pharmacist's CPD plan.
Accreditation number: CX110022p.

PSA is authorised by the Australian Pharmacy Council to accredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Update on Gout :: Debbie Rigby : 22/9/2011 : Learning objectives

After completing this activity, pharmacists should be able to:

  • describe the mechanisms underlying hyperuricaemia
  • state the risk factors for development of gout
  • identify drug-related causes of gout
  • list the treatment options for acute gout and prevention of gout
  • counsel patients on lifestyle modification.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 6.1.2, 6.2.1, 7.1.2, 7.1.3, 7.1.4.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point:  Accreditation number: CX110022o.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 39 :: Chris Alderman : 8/9/2011 : The next in our 2011 series of continuing education activities is the RGH E-Bulletin Digest No. 39.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 42-12 - 43-3 --> July - August 2011).

You can access these E-Bulletins individually here or as a group here.

After completing this activity, pharmacists should be able to:

  • Discuss issues relating to the “hCG” diet
  • Understand the risk factors for urinary retention related to inhaled anticholinergic drugs
  • Recognise a range of clinically important drug interactions
  • Locate support resources that may assist pharmacists caring for patients with cancer.

This activity has been accredited for 1 Group 2 CPD credit suitable for inclusion in an individual's pharmacist's CPD plan.
Accreditation number: CX110022n.

PSA is authorised by the Australian Pharmacy Council to accredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Polypharmacy - good or bad :: Jenny Gowan : 25/8/2011 : This AusPharm CE topic is Polypharmacy - it's been put together for us by Dr Jenny Gowan.

"Polypharmacy is usually defined as the use of five or more drugs, including prescribed, over-the-counter, and complementary medicines. Polypharmacy is also known as the use of multiple medications and is usually seen as a negative situation where an individual patient may be taking one or many more unnecessary medications among the group of appropriate medications."

The Learning Objectives for this activity are:

To enable the pharmacist when reviewing a list of medications  taken by a patient to:

  • identify possible unnecessary medications
  • recognise potential adverse reactions of caused by those medications
  • offer a rational approach to therapy
  • provide advice to assist in the safe withdrawal of medications to be ceased. 

Click here to do this Continuing Education activity. Or, if you prefer, you might like to take a look at our other CE activities here .

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 38 :: Chris Alderman : 4/8/2011 : The next in our 2011 series of continuing education activities is the RGH E-Bulletin Digest No. 38.

This CE activity assesses your understanding of four recent RGH Pharmacy E-Bulletins (Volumes 42-8 - 42-11  -->  June - July 2011).

After completing this activity, pharmacists should be able to:

  • Outline approaches to prophylaxis against recurrent urinary tract infections
  • Describe the approach to safe and effective dosing of gentamicin
  • Understand the nature of problems associated with the use of synthetic cannabis products
  • Discuss the management of intractable hiccups.

This activity has been accredited for 0.75 hours of Group 2 CPD (or 1.5 CPD credits) suitable for inclusion in an individual's pharmacist's CPD plan.
Accreditation number: CX110022l.

PSA is authorised by the Australian Pharmacy Council to accredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 37 :: Chris Alderman : 7/7/2011 : Welcome to Issue No 37 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss the interaction of St John's wort with contraceptive agents
  • Describe features of clozapine-induced haematological abnormalities
  • Outline recent evidence about optimal duration of statin therapy
  • Discuss the diagnosis and treatment of iron deficiency anaemia.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022j.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Asthma update :: Debbie Rigby : 23/6/2011 : Learning objectives

On completion of this activity, pharmacists will be able to:

  • Recognise the prevalence and incidence of asthma in Australia
  • Classify asthma in children and adults according to severity of symptoms and exacerbations
  • Select therapy based on severity of asthma symptoms
  • Identify different asthma phenotypes.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 6.1.2, 6.2.1, 7.1.2, 7.1.3, 7.1.4.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022i.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 36 :: Chris Alderman : 2/6/2011 : Welcome to Issue No 36 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Outline to clinical pharmacology of pegloticase
  • Discuss recent developments in the understanding of cardiovascular risk associated with NSAIDs
  • Describe recent evidence developments relating to the use of exanitide
  • Understand the different types of drug-induced tooth discoloration.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022g.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 35 :: Chris Alderman : 5/5/2011 : Welcome to Issue No 35 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Understand the possible influence of fish oil supplements on bleeding risk
  • Describe the relevant clinical profile of the long-acting olanzapine injection product
  • Discuss issues that relate to the clinical impact of polypharmacy in the elderly
  • Understand the basic clinical pharmacology of agomelatine.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022f.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Proton pump inhibitors and Pharmacist only medicines :: Jenny Gowan : 14/4/2011 : This AusPharm CE topic is Proton pump inhibitors as Pharmacist only medicines - it's been put together for us by Dr Jenny Gowan.

"The availability of Proton Pump inhibitors (PPIs) as Pharmacist only medicines has changed the management of patients requesting relief from short term heartburn and other gastro-oesophageal reflux disease. Pharmacist only PPIs are intended for short term use only and a person with recurring symptoms or alarm bells as listed below must be referred for further assessment. The availability of PPIs as Pharmacist only medicines also is convenient for those patients who have run out of their regular PPIs, or are away from home without supplies."

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022e.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 34 :: Chris Alderman : 31/3/2011 : Welcome to Issue No 34 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss the possible effects of inhaled corticosteroids on likelihood of diabetes mellitus
  • Understand principles influencing the administration of PPIs by the enteral tube route
  • Describe the clinical pharmacology of tocilizumab
  • Outline the use of intravesical gemcitabine for the treatment of superficial bladder cancer.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








A Good Clean-out - an update on poisoning management principles and techniques :: Professor Nerida Smith : 17/3/2011 : After completing this activity pharmacists should be able to describe:

  • basic information required to assess the risk of a poisoned patient developing severe complications 
  • the general first aid for poisonings
  • methods for decontaminating a patient following an ingested poison
    • what they are
    • How they work
    • When they might be used
    • Risks of use/precautions/when not to use.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022c.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 33 :: Chris Alderman : 3/3/2011 : Welcome to Issue No 33 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Compare the clinical pharmacology of rivaroxaban and dabigatran
  • Discuss potential hazards associated with co-prescription of benzodiazepines and opioids
  • Describe important factors to consider when considering the use of beta blockers for patients with COPD
  • Outline relevant considerations regarding the connection between statin treatment and nightmares.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Update on Calcium :: Debbie Rigby : 17/2/2011 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Assess the effect of calcium supplements on the risk of myocardial infarction
  • Appraise the limitations of the meta-analysis on the cardiovascular risk of calcium
  • Explain the benefits of optimal calcium intake from diet and supplements
  • Select appropriate dose of calcium supplements for individual patients
  • Counsel patients on the risks and benefits of calcium supplementation.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 32 :: Chris Alderman : 3/2/2011 : Welcome to Issue No 32 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Understand the clinical pharmacology of the combination oxycodone/naloxone product
  • Describe factors contributing to the development opioid induced hyepralgesia
  • Discuss pronicples of combined antihypertensive treatment
  • Understand potential drug-related problems with combined smoking cessation drugs and antidepressants.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Polypill or Christmas Cheer? :: Debbie Rigby : 16/12/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Identify risk factors for cardiovascular disease
  • Suggest non-pharmacological alternatives to reduce the risk of cardiovascular disease and stroke
  • Enjoy the health benefits of Christmas foods.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX100003v.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 31 :: Chris Alderman : 2/12/2010 : Welcome to Issue No 31 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Understand the clinical pharmacology of PDE4 inhibitors
  • Discuss factors contributing to the development of drug-induced lupus erythematosis
  • Describe the basis for hyperprolactinaemia secondary to antipsychotics
  • Understand the basis for hypogonadism related to long-term opioid treatment.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX100003u.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Irritable Bowel Syndrome :: Angus Thompson : 18/11/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • discuss the prevalence and diagnosis of IBS; and
  • discuss approaches to the management of IBS.

The competency standards addressed by this activity include (but may not be limited to) 1.3, 3.1, 3.2, 3.3, 6.1, 6.2, 6.3, 7.3.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX100003t.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 30 :: Chris Alderman : 4/11/2010 : Welcome to Issue No 30 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss the diagnosis and management of lithium-induced diabetes insipidus
  • Compare various treatment approaches available for management of constipation
  • Describe the clinical pharmacology of nebivolol, with an emphasis on use in management of heart failure
  • Understand the basis for drug interactions involving aspirin.

 

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX100003s.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Crushing tablets - issues to consider :: Jenny Gowan : 21/10/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Identify patients who may have swallowing difficulties
  • List common medicines which should not be crushed
  • Counsel patients about the risks of crushing tablets
  • Advise patients, doctors  and Aged Care Home staff about safety and procedures  to crush tablets
  • Utilise resources to provide options for medications  where crushing is not advised.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 29 :: Chris Alderman : 7/10/2010 : Welcome to Issue No 29 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Understand the clinical pharmacology of febuxostat
  • Describe the treatments approaches available for the management of interstitial cystitis
  • Describe the features of serotonin toxicity
  • Discuss the clinical pharmacology of dutasteride.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09049b.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Hormone therapy :: Debbie Rigby : 23/9/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Assess options to address quality of life and health concerns of menopausal women
  • Outline indications for hormone therapy
  • Counsel women on the risks and benefits of hormone therapy
  • Direct patients to evidence-based information resources.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 28 :: Chris Alderman : 9/9/2010 : Welcome to Issue No 28 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe causes of and treatments for hyperhydrosis
  • Understand recent clinical evidence relating to the consequences of vitamin D supplementation
  • Discuss factors influencing the anticoagulant activity of rivaroxaban
  • Outline appropriate treatment approaches for the management of simple constipation.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Cytochrome P450 interactions :: Debbie Rigby : 26/8/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Explain the mechanism of action of clopidogrel-PPI interaction
  • Assess the risks and benefits of PPI use with clopidogrel
  • Identify patients at high risk of adverse cardiovascular events due to the interaction
  • Advise prescribers and patients on how to manage concomitant use of clopidogrel and a PPI
  • Appraise drug interaction resources specific to CYP interactions.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 27 :: Chris Alderman : 12/8/2010 : Welcome to Issue No 27 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Understand the clinical implication of abnormal bleeding associated with SSRIs
  • Describe clinical factors that relevant to benzodiazepine use in the elderly
  • Identify clinical relating to the management of central post-stroke pain
  • List the caffeine content of various food and drinks commonly consumed in Australia.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 26 :: Chris Alderman : 29/7/2010 : Welcome to Issue No 26 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss the newly recommended approach to the use of colchicine for acute gout
  • Describe recent developments relating to the treatment of restless legs syndrome
  • Describe the clinical pharmacology of moxonidine
  • List clinical issues relating to the therapeutic use of melatonin.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX110022k.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Personalised Medicine and Pharmacogenomics :: Michael and Wassana Sorich : 15/7/2010 :

Learning objectives

After completing this activity, pharmacists should be able to:

  • Explain the purpose of personalised medicine and the contribution of pharmacogenomics
  • Discuss the barriers to and drivers for the use of personalised medicine
  • Compare and contrast examples of major current and emerging pharmacogenomic markers.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09049a.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 25 :: Chris Alderman : 1/7/2010 : Welcome to Issue No 25 of the RGH Pharmacy E-Bulletin CPD Digest.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Identify the relevant clinical issues relating to amiodarone-induced thyrotoxicosis
  • Discuss the use of complementary products for the management of menopausal symptoms
  • Describes principles relevant to the use of duloxetine for the management of diabetic neuropathy.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09049a.

 

 

 

 

 

 

 

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Drugs and driving: the role of the pharmacist in assisting with road safety for older road users :: Jenny Gowan : 17/6/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Identify medical conditions which may impact on driving skills
  • List common prescribed  and non prescription products which are known to impact on driving skills
  • Counsel patients about the risks of driving impairment
  • Advise patients and doctors on strategies to reduce risk of driving impairment.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048z.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 24 :: Chris Alderman : 3/6/2010 : Welcome to Issue No 24 of the RGH Pharmacy E-Bulletin CPD Digest. After completing this activity, pharmacists should be able to:

  • Understand general principles relating to the therapeutic use of prostanoid compounds
  • Discuss the clinical pharmacology and therapeutic application of ustekinumab
  • Describe the therapeutic applications of fish oil derivatives
  • Discuss clinical aspects of the interaction between grapefruit juice and statin drugs.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048y.

 

 

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Parkinson's disease :: Debbie Rigby : 20/5/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Understand the signs and symptoms of Parkinson's disease
  • Compare the pharmacotherapeutic management options
  • Counsel patients on the non-motor symptoms
  • Advise patients and doctors on the therapeutic management of common comorbidities.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048x.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 23 :: Chris Alderman : 6/5/2010 : Welcome to Issue No 23 of the RGH Pharmacy E-Bulletin CPD Digest. After completing this activity, pharmacists should be able to:

  • Understand general principles to apply in the conversion of opioid doses
  • Indentify important clinical issues relating to migraine in menopausal women
  • Describe drug interaction attributable to the effects of smoking
  • Discuss recently elucidated information about vaccines directed against malignant melanoma.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048w.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Conjunctivitis :: Greg Peterson : 22/4/2010 : Learning objectives

After completing this activity, pharmacists should be able to discuss:

  • the features and causes of conjunctivitis; and
  • approaches to the management of infective conjunctivitis, including the rational use of topical antibiotics.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048v.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 22 :: Chris Alderman : 8/4/2010 : Welcome to Issue No 22 of the RGH Pharmacy E-Bulletin CPD Digest. After completing this activity, pharmacists should be able to:

  • Discuss risk factors for over-anticoagualtion
  • Outline considerations that should be taken into account with therapeutic drug monitoring
  • Describe recent developments in connection to monthly bisphosphonate therapy
  • Identify principles that can be used to estimate equianalgesic doses of opioids.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048u.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Wound Care :: Natalie Carswell : 25/3/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Identify the components of a comprehensive wound assessment
  • Discuss traditional wound healing compared with the more modern moist wound healing
  • Discuss the aim of an 'ideal' wound dressing
  • Identify the classification and properties of wound dressing categories.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048t.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 21 :: Chris Alderman : 11/3/2010 : Welcome to Issue No 21 of the RGH Pharmacy E-Bulletin CPD Digest. After completing this activity, pharmacists should be able to:

  • Outline important new developments in the management of TIAs
  • Describe recent concerns in connection to the safety of drugs used in the management of obesity
  • Discuss risk factors for drug-induced myopathy syndromes
  • Identify serious drug interactions with medications used in the management of gout

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048s.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Headache and OTC analgesics :: Debbie Rigby : 25/2/2010 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Identify risk factors for adverse drug events with analgesics
  • Differentiate between types of chronic headache syndromes
  • Appraise patients for medication overuse headaches
  • Counsel patients on risks of overuse of analgesics and anti-migraine products.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048r.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 20 :: Chris Alderman : 11/2/2010 : Welcome to Issue No 20 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in this issue are:

  • Menopausal symptoms in women with history of breast cancer
  • Pharmacological therapies for androgenetic alopecia
  • Anaphylaxis with iodinated contrast media
  • Dabigatran – the new warfarin?

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 2 points:  Accreditation number: CX09048p.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 19 :: Chris Alderman : 17/12/2009 : Welcome to Issue No 19 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in this issue are:

  • Describe clinical aspects and epidemiology of treatment-emergent affective switch
  • Discuss the clinical pharmacology of cilostazol
  • Identify benefits of and barriers to the use of bar code technology in dispensing
  • Explain the relative merits of rate and rhythm control in the management of AF.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 point. Accreditation number: CX09048o.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Tests of the Blood Elements and Bleeding Risk :: Peter Tenni : 10/12/2009 : Learning objectives

After completing this activity, pharmacists should be able:

  • To know the major reasons for use of haematological laboratory tests by pharmacists
  • To know the common causes of haemoglobin and platelet count changes
  • To be able to differentiate the type of anaemia from standard haematological tests
  • To know the common drugs associated with changes of platelet counts
  • To understand the different coagulation tests and how they differentiate platelet from clotting factor disorders

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 points. Accreditation number: CX090048n.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Competency: The competency standards addressed by this activity include 3.2.6 (at least).

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








DEMENTIA - Reducing The Risks :: Debbie Rigby : 3/12/2009 : Learning objectives

After completing this activity, pharmacists should be able to:

  1. Identify risk factors for dementia and cognitive decline.
  2. List lifestyle modifications that may reduce the risk for dementia.
  3. Describe cardiovascular risk factors associated with a higher risk for dementia.
  4. Counsel patients on interventions to prevent or reduce the risk of dementia.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090048n.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 18 :: Chris Alderman : 26/11/2009 : Welcome to Issue No 18 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in this issue are:

  • Understand the nature of the possible link between insulin glargine and cancer risk
  • Describe important clinical aspects of Progressive Multifocal Leucoencephalopathy
  • Discuss drug-induced gingival hyperplasia
  • Describe the clinical pharmacology of prasugrel.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 point. Accreditation number:CX09048l.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Biostatistics - Building on the basics :: Chris Alderman : 19/11/2009 : "In a previous review, the need for pharmacists, doctors and others involved in the interpretation of information about therapeutics to have a basic working understanding of the principles of biostatistics was discussed. Issues such as sampling, types of data, data dispersal and measures of central tendency were covered. In this update, we build upon these concepts to develop a more detailed understanding of inferential statistical techniques."

Learning objectives:

  • Understand basic principles relevant to hypothesis testing in research
  • Describe the types of error encountered in statistical procedures
  • Discuss basic inferential statistical tests 
  • Describe the basic principles of tests of relatedness and survival curves

The competency standards addressed by this activity include (but may not be limited to) 3.1.2.; 3.1.3; 3.1.5; 3.2.2; 4.2.1; 4.2.2; 4.2.3, 7.3.2; 7.3.4.

Successfull completion of this activity is demonstrated by answering five of the six multiple choice questions correctly.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090048k.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Anxiety disorders in old age :: Juanita Westbury : 12/11/2009 : Learning objectives

After completing this activity, pharmacists should be able to:

  1. Describe the five types of anxiety disorders and identify differences in anxiety symptoms when they present in later life
  2. Discuss the current, evidence based treatment of anxiety disorders in older people
  3. Recognise the symptoms of anxiety in older people and encourage them to seek help from GPs and psychologists

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090048j.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








β-blockers in airway disease :: Debbie Rigby : 5/11/2009 : Learning objectives

After completing this activity, pharmacists should be able to:

  1. Identify benefits of β-blockers in cardiovascular disease
  2. Be aware of the potential benefits of β-blockers in airway disease
  3. Counsel patients on benefits and risks of β-blockers in airway disease

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090048i.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 17 :: Chris Alderman : 29/10/2009 : Welcome to Issue No 17 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in this issue are:

  • Understand important drug interactions with urinary alkalinisers
  • Describe important clinical aspects of refeeding syndrome
  • Discuss the management of thiamine deficiency
  • Describe the clinical pharmacology of bevacizumab

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 point. Accreditation number:CX09048h.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Macular Degeneration - Role of Complementary Medicines :: Debbie Rigby : 22/10/2009 : Learning objectives

After completing this activity, pharmacists should be able to:

  1. Be aware of signs and symptoms of macular degeneration
  2. Counsel patients on modifiable risk reduction strategies
  3. Select appropriate evidence-based complementary medicines
  4. Refer patients to a medical practitioner when appropriate

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090048g.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Scabies :: Leanne Stafford : 8/10/2009 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the cause, typical signs and symptoms and diagnosis of scabies, plus the spread and prevalence of, and risk factors for, infestation with the scabies mite.
  • Discuss the current, evidence-based treatment of scabies infestation in various patient populations.
  • Assist patients to promote the effective use of scabicidal agents, and advise on appropriate complementary strategies to prevent re-infestation.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1.25 points. Accreditation number: CX090048f.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 16 :: Chris Alderman : 1/10/2009 : Welcome to Issue No 16 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in this issue are:

  • Inhaled insulin
  • Insomnia in the elderly
  • Drug-induced acute pancreatitis
  • Methylnaltrexone

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 point. Accreditation number:CX09048e.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Basic Biostatistics - An introduction for Pharmacists :: Chris Alderman : 24/9/2009 : "There are three kinds of lies: lies, damned lies, and statistics." This phrase, often attributed to the 19th Century British Prime Minister Benjamin Disraeli, symbolises the difficulty, mistrust, and even fear that many people react with when required to interpret the use of statistical techniques. Despite this, a basic understanding of the important principles of biostatistics is an almost inescapable requirement for any health worker involved in clinical decision making.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss the issues that are important to consider in sampling techniques in studies
  • Describe the different characteristics of various forms of data scale used in statistics
  • Understand the various measures of data dispersal used in statistics
  • Identify the characteristics of various measures of central tendency

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Menopause - vasomotor symptoms :: Debbie Rigby : 17/9/2009 :
Learning objectives

After completing this activity, pharmacists should be able to:

  • Recognise vasomotor symptoms associated with menopause
  • Outline the treatment options and the associated risk/benefits
  • Counsel women on the risks/benefits of therapies to treat vasomotor symptoms of menopause

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090048c.

PSA is authorised by the Australian Pharmacy Council to acredit providers of CPD activities for pharmacists that may be used as supporting evidence of continuing competence.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Insulin therapy in the 21st century :: Leanne Stafford : 10/9/2009 : Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss the therapeutic actions of insulin, and the place in therapy of the newer insulin analogues
  • Describe the commonly prescribed insulin regimens and the management of insulin-related adverse effects
  • Assist patients with, and direct them to appropriate resources regarding, the administration of their insulin therapy.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX0900486b.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

 


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 15 :: Chris Alderman : 3/9/2009 : Welcome to Issue No 15 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in this issue are:

* Interaction between folate and phenytoin
* Zoledronic acid for osteoporosis
* Glucosamine in osteoarthritis: Update of the evidence
* Adverse effects of cholinesterase inhibitors

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 point. Accreditation number: CX090048.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Grapefruit Interactions :: Debbie Rigby : 27/8/2009 : Learning objectives

After completing this activity, pharmacists should be able to:

  1. Identify the mechanism of grapefruit juice-drug interactions and drugs involved with significant grapefruit-drug interactions
  2. Describe potential effects of grapefruit juice-drug interactions
  3. Discuss medications that may be affected and degree of risk associated with common interacting medications
  4. Identify effective alternative medications that do not interact
  5. Explain drug interaction risk factors and effective, alternative medications for patients.

Competency standards addressed: 3.2.2, 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2, 6.2.5, 6.3.2.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022z.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Understanding Common Biochemistry Tests :: Peter Tenni : 20/8/2009 : Learning objectives

After completing this activity, pharmacists should be able to:

  • To know the major reasons for use of laboratory tests by pharmacists
  • To know the common causes of sodium, potassium, urea and creatinine concentration changes
  • To know the common drugs associated with concentration changes of sodium, potassium, urea and creatinine
  • To be aware of the pattern of biochemical tests associated with under and overhydration

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022y.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.

 


Click here to do this Continuing Education activity.








Dry Eyes :: Debbie Rigby : 13/8/2009 :
Learning objectives

After completing this activity, pharmacists should be able to:

  • Recognise that dry eye syndrome is a common disorder in the older person
  • Understand the role of tears in eye health
  • Identify common signs and symptoms of dry eyes
  • Identify medical conditions and lifestyle issues that may predispose patients to dry eyes
  • List common medications associated with dry eyes
  • Evaluate drug therapies for the treatment and prevention of dry eyes
  • Counsel patients on the most appropriate treatment  
  • Outline the role of the pharmacist in discussing management of dry eyes with patients

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022z.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 14 :: Chris Alderman : 6/8/2009 : Welcome to Issue No 14 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in Issue No 14 are:

* Total parenteral nutrition
* Antimicrobials for Vancomycin Resistant Enterococci
* Neuramidase inhibitors and H1 N1 influenza 09
* Medical records and adverse drug reactions

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 point. Accreditation number: CX090022w.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Update on Fish Oils and Cardiovascular Disease :: Angus Thompson and Tonie Miller : 23/7/2009 : After completing this activity, pharmacists should be able to:

  • Discuss the roles played by marine n-3 PUFAs in the prevention and management of cardiovascular disease.
  • Provide advice to pharmacy clients on intake of marine n-3 PUFAs from both dietary and supplemental sources relevant to their individual needs.
  • Direct patients to additional sources of information on the role of marine n-3 PUFAs in cardiovascular disease.

Competency standards addressed: 6.3.1, 7.3.2, 7.3.3, 8.4.3.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022v.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Nocturnal leg cramps :: Debbie Rigby : 16/7/2009 :
Learning objectives

After completing this activity, pharmacists should be able to:

  • Recognise that leg cramps are a common disorder
  • Identify medical conditions that may predispose patients to leg cramps
  • List common medications associated with leg cramps
  • Discuss the benefits on physical and non-drug interventions
  • Evaluate drug therapies for the treatment and prevention of leg cramps
  • Counsel patients on the unfavourable risk/benefit of treatment with quinine 
  • Outline the role of the pharmacist in discussing management of leg cramps with patients

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 points. Accreditation number: CX090022u.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Rheumatoid Arthritis :: Anna McClure : 9/7/2009 :  

Learning objectives

After completing this activity, pharmacists should be able to:

  • Recognise the signs and symptoms of rheumatoid arthritis (RA) and how these differ from osteoarthritis (OA)
  • Recognise the importance of controlling inflammation in slowing disease progression and managing symptoms
  • Understand the therapeutic strategy for the treatment of RA, including the role of biologic therapies
  • For patients taking DMARDs, recognise the importance of monitoring for toxicity and efficacy.
  • Understand the role of non-pharmacologic therapy

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1.5 points. Accreditation number: CX090022t.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 13 :: Chris Alderman : 2/7/2009 : Welcome to Issue No 13 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in Issue No 13 are:

  • Statins and haemorrhagic stroke risk
  • The polypill
  • Metoclopramide and movement disorders
  • Hydromorphone prolonged-release (Jurnista)

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 point. Accreditation number: CX090022s.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Proton pump inhibitors adverse effects :: Debbie Rigby : 25/6/2009 :
Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the association of long-term proton pump inhibitor use with the risk for community-acquired pneumonia, hip fractures, interstitial nephritis and C. difficle infection.
  • Advise general practitioners on management of concomitant use of clopidogrel and PPIs
  • Counsel patients on the risks and benefits of long-term PPI use

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022v.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Update on Dietary Fats and their role in Cardiovascular Disease :: Angus Thompson, Tonie Miller and Lisa Murphy : 18/6/2009 : After completing this activity, pharmacists should be able to:

* Discuss the association between dietary fat intake and cardiovascular health
* Provide advice on making changes to dietary fat intake to improve health outcomes 
* Direct patients to additional sources of information on dietary fat intake and health

Competency standards addressed: 6.3.1, 7.3.2, 7.3.3, 8.4.3.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 points. Accreditation number: CX090022q.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Osteoarthritis :: Anna McClure : 4/6/2009 :  

Learning objectives

After completing this activity, pharmacists should be able to:

  • Recognise the signs and symptoms of osteoarthritis (OA)
  • Understand the risk factors for OA
  • Evaluate therapeutic options for the treatment of OA, including non-pharmacologic therapies
  • Understand the complexities of COX-II selective and non-selective NSAIDs
  • Recognise the role of the pharmacist in the management of OA, including when to refer

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1.25 point. Accreditation number: CX090022p.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








PMS and PMDD – premenstrual disorders :: Debbie Rigby : 28/5/2009 :
Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the signs and symptoms of PMS and PMDD
  • Select appropriate therapy for the management of premenstrual disorders
  • Advise women with PMS on over-the-counter medications and lifestyle modifications
  • Refer patients to a medical practitioner when appropriate

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022o.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 12 :: Chris Alderman : 21/5/2009 : Welcome to Issue No 12 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in Issue No 12 are:

  • Renal colic
  • Complementary and alternative medicines in RA
  • Respimat® inhaler
  • Premarin® and Premia Continuous®

After completing this activity, pharmacists should be able to:

  • Have an understanding of the diagnosis and management of renal colic
  • Describe recent evidence in relation to the use of complementary therapy for rheumatoid arthritis
  • Understand the characteristics of the Respimat® inhaler device
  • Discuss alternatives to conjugated oestrogen products

The competency standards addressed by this activity include (but may not be limited to) 3.1.2.; 3.1.3; 3.1.5; 3.2.2; 4.2.1; 4.2.2; 4.2.3, 7.3.2; 7.3.4.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 points. Accreditation number: CX090022o.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Fungal skin diseases :: Colin Curtain : 14/5/2009 :
On completion of this module, the pharmacist should be able to:

  • Discuss the causes and risk factors for tinea.
  • Identify tinea.
  • Offer appropriate treatment or referral.

The competency standards addressed by this activity include (but may not be limited to) 3.1, 3.2, 3.3, 6.1 ,6.2, 6.3.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 points. Accreditation number: CX090022n.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 11 :: Chris Alderman : 7/5/2009 : Welcome to Issue No 11 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in Issue No 11 are:

  • Desvenlafaxine for depression
  • Denosumab
  • Clopidogrel and PPIs
  • Antithrombin deficiency

After completing this activity, pharmacists should be able to:

  • Have an understanding of the basic clinical pharmacology of desvenlafaxine
  • Describe basic characteristics of the novel osteoporosis treatment, denosumab
  • Understand the nature of the possible interaction between clopidogrel and PPIs
  • Discuss the clinical implications and management of antithrombin III deficiency

The competency standards addressed by this activity include (but may not be limited to) 3.1.2.; 3.1.3; 3.1.5; 3.2.2; 4.2.1; 4.2.2; 4.2.3; 7.3.2; 7.3.4.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 points. Accreditation number: CX090022l.

Click here to do this Continuing Education activity.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Peptic ulcer disease, non-steroidal anti-inflammatory drugs, Helicobacter pylori and proton pump inhibitors :: Jenny Casanova : 30/4/2009 : After completing this activity, pharmacists should be able to:

  • Describe common signs and symptoms of peptic ulcer disease and distinguish it from gastro-oesophageal reflux disease.
  • Identify the alarm symptoms which indicate need for an urgent endoscopy
  • List medications which commonly cause ulcers and gastritis
  • Recommend first-line Helicobacter pylori eradication therapy based on Australian resistance patterns
  • Consider the risks of long term acid suppression with PPIs
  • Identify situations where ulcer prophylaxis is appropriate

Click here to do this Continuing Education activity.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022k.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Hypertension :: Angus Thompson : 23/4/2009 :
On completion of this module, the pharmacist should be able to discuss:

  • Discuss the factors affecting choice of antihypertensive treatment
  • Discuss current blood pressure treatment targets
  • Briefly discuss the concept of overall cardiovascular risk

The competency standards addressed by this activity include (but may not be limited to) 3.1.2, 3.1.3, 3.1.4.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022k.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS and The Australian Medicines Handbook (AMH).


Click here to do this Continuing Education activity.








Gout :: Debbie Rigby : 16/4/2009 : Gout is a common inflammatory arthritis usually presenting with a sudden onset and has a tendency to recur. It is predominantly a disease of middle-aged men, but there is a gradually increasing prevalence in both men and women in older age groups. Women usually develop gout after menopause. It is estimated that 1 to 2% of adults in Australia have the disorder.  The incidence is substantially higher in Maoris at 6.4%.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 points. Accreditation number: CX090022j.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 10 :: Chris Alderman : 2/4/2009 : Welcome to Issue No 10 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in Issue No 10 are:

  • Natalizumab for multiple sclerosis
  • Mouth care
  • Anticholinergic agents, cognition and heat-related illness
  • Educational visiting service from clinical pharmacists

After completing this activity, pharmacists should be able to:

  • Understand the relevant factors in the clinical use of natalizumab
  • Describe the principles of educational visiting as a means to improve prescribing of renally cleared drugs
  • Describe fundamental aspects of mouth care practices
  • Indentify important adverse effects arising form the use of anticholinergic drugs

The competency standards addressed by this activity include (but may not be limited to) 3.1.2.; 3.1.3; 3.1.5; 3.2.2; 4.2.1; 4.2.2; 4.2.3; 7.3.2; 7.3.4.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 0.75 point. Accreditation number: CX090022h.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Psychosis and antipsychotics: selected clinical issues :: Chris Alderman and Anita Marwood : 26/3/2009 :
This activity is based on a critical area of contemporary therapeutics, addressing the important issue of a serious mental illness and the treatments that can be used for the management of these conditions.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1.5 points. Accreditation number: CX090022g.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








The management of asthma :: Bonnie Bereznicki : 19/3/2009 :  


On completion of this module, the pharmacist should be able to:

  • Assess a patient’s asthma control and refer if necessary
  • Identify the concepts of the Australian Asthma Management Plan
  • Recognise the place in therapy of an Asthma Action Plan and be able to advise patients
  • Analyse the use of ‘relievers’, ‘preventers’, ‘symptom controllers’ and ‘maintenance and reliever’ treatment and their place in therapy.
  • Recognise the pharmacist’s role in asthma management.

The competency standards addressed by this activity include (but may not be limited to) 3.1.1, 3.1.2, 3.1.3, 3.1.4, 3.2.1, 3.2.2, 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1.25 points. Accreditation number: CX090022f.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








AusPharm CE: OTC management of Urinary Tract Infections (UTIs) :: Debbie Rigby : 12/3/2009 :
Learning objectives

After completing this activity, pharmacists should be able to:

  1. Be aware of signs and symptoms of urinary tract infections
  2. Select appropriate antibiotic therapy for treating UTIs
  3. Identify OTC medications for preventing UTIs
  4. Refer patients to a medical practitioner when appropriate

Competency standards addressed: 3.2.2, 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2, 6.2.5, 6.3.2.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for .75 points. Accreditation number: CX090022e.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








RGH Pharmacy E-Bulletin CPD Digest - Issue No 9 :: : 5/3/2009 : Welcome to Issue No 9 of the RGH Pharmacy E-Bulletin CPD Digest. The topics covered in Issue No 9 are:

  • Christmas Edition - Best wishes for the festive season (interpreting clinical trials)
  • Rivaroxaban
  • Ambulatory glycaemic control - recent developments
  • Parasomnias and psychiatric adverse effects with zolpidem

After completing this activity, pharmacists should be able to:

  • Identify factors relevant in the interpretation of clinical trials
  • Be aware of the adverse effects associated with zolpidem
  • Understand the nature of parasomnias
  • Understand recent developments in relation to glycaemic control for diabetic patients
  • Apply a working knowledge of the clinical pharmacology of rivaroxaban

The competency standards addressed by this activity include (but may not be limited to) 3.1.2.; 3.1.3; 3.1.5; 3.2.2; 4.2.1; 4.2.2; 4.2.3; 7.3.2; 7.3.4.

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022a.

 AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Education activity.








Osteoporosis in men :: Debbie Rigby : 26/2/2009 :
Learning objectives

After completing this activity, pharmacists should be able to:

  • Understand the prevalence and incidence of osteoporosis in men
  • Identify risk factors for osteoporosis in men
  • Be aware of the evidence for treatment of osteoporosis in men
  • Counsel male patients on benefits of calcium and vitamin D supplementation

Competency standards addressed: 3.1.2 and 4.3.3

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022c.

Click here to do this Continuing Education activity.

 

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS and The Australian Medicines Handbook (AMH).


Click here to do this Continuing Education activity.








AusPharm CE: Vaginal thrush :: Ella Jeffrey : 19/2/2009 :
On completion of this module, the pharmacist should be able to discuss:

* the causes of vaginitis; and
* approaches to the management of vaginitis, particularly vulvovaginal candidiasis.

The competency standards addressed by this activity include (but may not be limited to) 3.1.1, 3.1.2, 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2, 6.3.1, 6.3..

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022a.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS and The Australian Medicines Handbook (AMH).


Click here to do this Continuing Education activity.








Statin induced myopathy :: Debbie Rigby : 12/2/2009 :
After completing this activity, pharmacists should be able to:

  • Identify risk factors for statin-induced myopathy
  • Be aware of the signs and symptoms of statin-induced myopathy
  • Counsel patients on the benefits and risks of statin therapy

The competency standards addressed by this activity include (but may not be limited to) 3.1.2 and 4.3.3. 

This activity has been accredited by the Pharmaceutical Society of Australia as a Group 2 activity for 1 point. Accreditation number: CX090022a.

Click here to do this Continuing Education activity.

AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS and The Australian Medicines Handbook (AMH).


Click here to do this Continuing Education activity.









About this page 

These activities will take approximately 30 minutes to complete and has been formally recognised by the Pharmaceutical Society of Australia (Recognition No: CR08-0012 : 1 CPD&PI point), The Australian Association of Consultant Pharmacy and The Australian College of Pharmacy Practice and Management. To add your PSA, AACP or ACPPM member number to our database (so you can receive credit for completing this activity) click here.


Australian Medicines Handbook

Mediflags

Griffith University Weekend Courses in Integrative Medicine

mdBriefCase

Webstercare

eMIMS

Johnson & Johnson

APF 22: an everyday guide to pharmacy practice

MIMS

Fred Health

Fred Dispense



Australian Journal of Pharmacy

PostScript Magazine

PCCA

Pharmacy Pro

Click here to advertise here

APPCo

JR Pharmacy Services

Johnson & Johnson

Australian College of Pharmacy Practice & Management

 

All images copyright © www.auspharm.net.au pty ltd, 2010, or their respective owners.